# Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients

> **NCT04853719** · PHASE4 · COMPLETED · sponsor: **Science Valley Research Institute** · enrollment: 88 (actual)

## Conditions studied

- Peripheral Artery Disease
- Intermittent Claudication

## Interventions

- **DRUG:** Rivaroxaban 2.5 Mg Oral Tablet

## Key facts

- **NCT ID:** NCT04853719
- **Lead sponsor:** Science Valley Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-20
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04853719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04853719, "Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04853719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*